1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-169827
    EMD-132338
    Antagonist
    EMD-132338 is a GPIIb/IIIaIIbβ3) antagonist that inhibits platelet aggregation. EMD-132338 can be utilized in antithrombosis research.
    EMD-132338
  • HY-171331
    AB-3PRGD2
    AB-3PRGD2 is a radiotherapeutic agent targeting integrin αvβ3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells.
    AB-3PRGD2
  • HY-A0300
    Cyclopeptide-5
    Antagonist
    Cyclopeptide-5 (EMD 270179) is an αvβ3 antagonist that can improve PAF-induced increased adhesion of sickle red blood cells, capillary post-obstruction, and enhance blood flow dynamics. Cyclopeptide-5 also has cytotoxic effects.
    Cyclopeptide-5
  • HY-P990398
    Anti-DC-SIGN/CD209 Antibody
    Anti-DC-SIGN/CD209 Antibody is a CHO-expressed humanized antibody that targets DC-SIGN/CD209. Anti-DC-SIGN/CD209 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DC-SIGN/CD209 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-DC-SIGN/CD209 Antibody
  • HY-153481
    ATL 1102
    Inhibitor
    ATL 1102 is a novel second-generation antisense oligonucleotide to CD49d mRNA
    ATL 1102
  • HY-139202
    XVA143
    Inhibitor
    XVA143, an α/β I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo.
    XVA143
  • HY-10304
    Orbofiban
    Orbofiban is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
    Orbofiban
  • HY-P991434
    SAN-300
    Inhibitor
    SAN-300 is a human IgG1 monoclonal antibody (mAb) targeting ITGA1/VLA-1. SAN-300 can be used in Rheumatoid arthritis research.
    SAN-300
  • HY-P10038
    mP6
    Inhibitor
    mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells.
    mP6
  • HY-168521
    αvβ6-IN-1
    Inhibitor
    αvβ6-IN-1 (compound 28) is a potent and orally active αvβ6 integrin inhibitor with a pIC50 value of 8.1. αvβ6-IN-1 has the potential for the research of idiopathic pulmonary fibrosis.
    αvβ6-IN-1
  • HY-117824
    L-703014
    Antagonist
    L-703014 is a fibrinogen receptor antagonist, with the IC50 of 94 nM, that acts as a novel parenteral and potential oral antithrombotic agent.
    L-703014
  • HY-P6010
    αvβ6-BP
    αvβ6-BP is a selective αvβ6 binding peptide, and can be used for molecular imaging.
    αvβ6-BP
  • HY-P1187A
    HSDVHK-NH2 TFA
    Antagonist
    HSDVHK-NH2 TFA is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM).
    HSDVHK-NH2 TFA
  • HY-145314
    TC113
    TC113 is a c(RGDyK)-Based conjugate of Gemcitabine (GEM). TC113 could be internalized by A549 cells through integrin αvβ3. TC113 shows potent antiproliferative properties against WM266.4 and A549 cells.
    TC113
  • HY-153998
    BT100 sodium
    Inhibitor
    BT100 (sodium), a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis.
    BT100 sodium
  • HY-19229
    TAK-029
    TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases.
    TAK-029
  • HY-156521
    αvβ1 integrin-IN-2
    Inhibitor
    αvβ1 integrin-IN-2 (compound 32) is a potent inhibitor of integrins ανβ1 and α5β1 with IC50s of 0.9 nM,and 33 nM,respectively. αvβ1 integrin-IN-2 also inhibits other integrins with ,,IC50s of 380 nM (ανβ3),280 nM (ανβ5),230 nM (ανβ6),87 nM (ανβ8),respectively,in SPRA assay.
    αvβ1 integrin-IN-2
  • HY-122230
    UR-3216
    Inhibitor
    UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research.
    UR-3216
  • HY-12159
    MK-0668
    Antagonist
    MK-0668 is an amino acid-based, potent antagonist of unactivated VLA-4, with an IC50) of 0.13 nM in human whole blood. And MK-0668 exhibits IC50s of 0.19 nM in dogs, 0.21 nM in rhesus monkeys, and 0.4 nM in rats.
    MK-0668
  • HY-17369BS
    Tirofiban-d9
    Antagonist
    Tirofiban-d9 is deuterium labeled Tirofiban.
    Tirofiban-d<sub>9</sub>
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.